clarify operating performance of the Company three-month for the Quarter 2/2019 ended 30 June 2019 as the following: change Q2/2019 Q2/2018 increase (decrease) Sales 172.5 240.8 -28.4% Other income 17.8 0.6
follows; Unit: THB million Three-month period % Change +/(-) Six-month period % Change Q2’19 Q1’20 Q2’20 QoQ YoY 6M’19 6M’20 +/(-) 1. Revenue from sales and contract work 2.7 4.7 5.5 16.7% 102.9% 5.9 10.2
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
) operating results based on its reviewed consolidated financial statements ended 31 March 2018 as follows. Highlights on Q1-2018 Operating results Unit : Million Baht Q1-18 Q1-17 Q4-17 % Change Amount % Amount
Operation : Consolidated Profit & Loss Statement 4Q 4Q % 12 mth 12 mth % Unit : THB million 2019 2018 change 2019 2018 change Revenue from non-social security 285.64 220.70 29% 1,041.26 911.16 14% Revenue
amount of THB. 25.8 million whereas there was no such item in 3Q17 profit & loss statement. Operation : Consolidated Profit & Loss Statement 3Q 3Q % 9 mth 9 mth % Unit : THB million 2017 2016 change 2017
by the Company’s auditor can be summarized as follows: The Company’s Performance for the yearly end in 2017 showed a Net Profit of 6.8 million baht, higher than 2016 by 1.2 million baht or an increased
follows: The Company’s Performance for the yearly end in 2017 showed a Net Profit of 6.4 million baht, higher than 2016 by 1.2 million baht or an increased by 20.8%. This represent net profit margin of 0.91
follows: (Unit : Baht million) Consolidated Results* Year 2019 Year 2018 Increase / (Decrease) % Change Revenue from sales 120.13 214.32 (94.19) -43.95% Other revenues 3.00 0.24 2.76 1,152.06% Total
Total Change Increase (Decrease) Quarter 3 Quarter 3 Quarter 3 Quarter 3 2017 2016 2017 2016 2017 2016 Amount % Total Revenues 8,600 8,059 183 251 8,783 8,310 473 6% Total Expenses (7,760) (7,178) (158